CN101534641A - 治疗高胆固醇血症和动脉粥样硬化的方法和组合物 - Google Patents

治疗高胆固醇血症和动脉粥样硬化的方法和组合物 Download PDF

Info

Publication number
CN101534641A
CN101534641A CNA2007800189793A CN200780018979A CN101534641A CN 101534641 A CN101534641 A CN 101534641A CN A2007800189793 A CNA2007800189793 A CN A2007800189793A CN 200780018979 A CN200780018979 A CN 200780018979A CN 101534641 A CN101534641 A CN 101534641A
Authority
CN
China
Prior art keywords
compound
formula
atherosclerosis
hypercholesterolemia
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800189793A
Other languages
English (en)
Chinese (zh)
Inventor
G·S·霍塔米斯利尔
U·奥滋坎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of CN101534641A publication Critical patent/CN101534641A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNA2007800189793A 2006-03-22 2007-03-22 治疗高胆固醇血症和动脉粥样硬化的方法和组合物 Pending CN101534641A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78515606P 2006-03-22 2006-03-22
US60/785,156 2006-03-22

Publications (1)

Publication Number Publication Date
CN101534641A true CN101534641A (zh) 2009-09-16

Family

ID=38541674

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800189793A Pending CN101534641A (zh) 2006-03-22 2007-03-22 治疗高胆固醇血症和动脉粥样硬化的方法和组合物

Country Status (7)

Country Link
US (1) US20090312297A1 (https=)
EP (1) EP2001484A4 (https=)
JP (1) JP2009530398A (https=)
CN (1) CN101534641A (https=)
AU (1) AU2007230989A1 (https=)
CA (1) CA2679608A1 (https=)
WO (1) WO2007111992A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103919787A (zh) * 2014-04-17 2014-07-16 厦门大学 牛磺熊脱氧胆酸及其可接受的盐的制药用途
CN108697677A (zh) * 2016-02-26 2018-10-23 燿石治疗公司 对正接受降脂疗法的纯合型家族性高胆固醇血症患者的治疗
CN110279702A (zh) * 2019-07-18 2019-09-27 西安交通大学医学院第一附属医院 胆汁酸衍生物在防治动脉粥样硬化药物中的应用
CN110559303A (zh) * 2019-09-24 2019-12-13 江西天元药业有限公司 降血脂预防治疗心脑血管病和动脉粥样硬化的精制熊胆粉
CN111344016A (zh) * 2017-10-02 2020-06-26 宝洁公司 用于抑制胆碱向三甲胺(tma)的转化的方法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080139520A1 (en) * 2006-08-22 2008-06-12 Jain Mahendra K Altering cholesterol and fat uptake by novel allosteric inhibitors of pancreatic phospholipase A2
JP2009078977A (ja) * 2007-09-25 2009-04-16 Japan Health Science Foundation 心筋の小胞体ストレス抑制剤
KR101064937B1 (ko) * 2009-06-16 2011-09-15 박상규 타우로우루소데옥시콜릭산 또는 그의 염을 포함하는 혈관재협착 예방 또는 치료용 약학 조성물
EP2599481A1 (en) * 2011-11-30 2013-06-05 Lunamed AG 4-phenylbutyric acid for the treatment or prevention of various diseases
US9872865B2 (en) 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
US20160051567A1 (en) * 2013-03-27 2016-02-25 Metselex, Inc. Prevention and treatment of kidney damage
JP6430736B2 (ja) * 2014-03-20 2018-11-28 株式会社ファンケル 新規ステロール系化合物およびこれを含有するコレステロール吸収阻害剤
CN106794165A (zh) 2014-10-15 2017-05-31 伯克和博耶纽约 单不饱和脂肪酸组合物和治疗动脉粥样硬化的应用
KR101555945B1 (ko) * 2014-11-27 2015-09-25 부산대학교 산학협력단 Ｔｕｄｃａ를 이용한 줄기세포 생물작용 활성 증가, 및 이를 포함하는 줄기세포 치료 보조제
EP3253381B1 (en) 2015-02-06 2020-11-11 Lonza Consumer Health Inc. Trimethylamine-n-oxide producing agent for treating atheroma formation
EA036404B1 (ru) 2015-02-06 2020-11-06 Интерсепт Фармасьютикалз, Инк. Фармацевтические композиции для комбинированной терапии
US11583542B2 (en) 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
KR102686453B1 (ko) * 2021-08-18 2024-07-17 전북대학교산학협력단 TUDCA 코팅된 나노입자 및 이를 포함하는 p-셀렉틴 리간드, p-셀렉틴 과발현 질병 치료용 조성물 및 진단용 영상 조영제
US12138272B2 (en) 2022-05-12 2024-11-12 Amylyx Pharmaceuticals, Inc. Methods and compositions for treating amyotrophic lateral sclerosis
WO2025054199A1 (en) * 2023-09-05 2025-03-13 Amylyx Pharmaceuticals, Inc. Compositions and methods for treating subjects with hepatic impairment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
IT1213390B (it) * 1986-11-28 1989-12-20 Gipharmex Spa Composizioni farmaceutiche ad uso orale del tipo a cessione controllata nel tempo contenenti composti a struttura steroidea attivi nelle alterazioni del metabolismo del colesterolo.
US5846964A (en) * 1993-07-19 1998-12-08 Tokyo Tanabe Company Limited Hepatitis C virus proliferation inhibitor
US6270954B1 (en) * 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
KR20050103185A (ko) * 2002-11-07 2005-10-27 리전츠 오브 더 유니버스티 오브 미네소타 출혈과 관련된 신경계 손상의 치료 방법
WO2006069371A1 (en) * 2004-12-22 2006-06-29 Baylor College Of Medicine A method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103919787A (zh) * 2014-04-17 2014-07-16 厦门大学 牛磺熊脱氧胆酸及其可接受的盐的制药用途
CN108697677A (zh) * 2016-02-26 2018-10-23 燿石治疗公司 对正接受降脂疗法的纯合型家族性高胆固醇血症患者的治疗
CN111344016A (zh) * 2017-10-02 2020-06-26 宝洁公司 用于抑制胆碱向三甲胺(tma)的转化的方法
CN111344016B (zh) * 2017-10-02 2022-04-05 宝洁公司 用于抑制胆碱向三甲胺(tma)的转化的方法
CN110279702A (zh) * 2019-07-18 2019-09-27 西安交通大学医学院第一附属医院 胆汁酸衍生物在防治动脉粥样硬化药物中的应用
CN110279702B (zh) * 2019-07-18 2022-09-02 西安交通大学医学院第一附属医院 胆汁酸衍生物在防治动脉粥样硬化药物中的应用
CN110559303A (zh) * 2019-09-24 2019-12-13 江西天元药业有限公司 降血脂预防治疗心脑血管病和动脉粥样硬化的精制熊胆粉

Also Published As

Publication number Publication date
US20090312297A1 (en) 2009-12-17
JP2009530398A (ja) 2009-08-27
EP2001484A2 (en) 2008-12-17
EP2001484A4 (en) 2010-04-21
AU2007230989A1 (en) 2007-10-04
WO2007111992A2 (en) 2007-10-04
WO2007111992A3 (en) 2008-11-06
CA2679608A1 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
CN101534641A (zh) 治疗高胆固醇血症和动脉粥样硬化的方法和组合物
ES2274013T3 (es) Combinaciones de activador(es) del receptor activado por el proliferador de los peroxisomas (ppar) e inhibidor(es)m de la absorcion de estelores y tratamientos para trastornos vasculares.
US20060073213A1 (en) Reducing ER stress in the treatment of obesity and diabetes
US20100075894A1 (en) Reducing er stress in the treatment of obesity and diabetes
CA3212583A1 (en) Compositions having improved bioavailability of therapeutics
JP2005526786A (ja) Ｄｍｘａａとｎｓａｉｄの抗癌的組み合わせ
CA2531836A1 (en) Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions.
AU2003245605A1 (en) Novel anticholesterol compositions and method for using same
US20140186438A1 (en) Compositions comprising epa and obeticholic acid and methods of use thereof
CA3101274A1 (en) Use of neutrophil elastase inhibitors in liver disease
EP1560579A1 (en) Cholesterol absorption inhibitors for the treatment of autoimmune disorders
JP6878596B2 (ja) Ｆｘｒアゴニストの組合せ
JP2019518022A (ja) 肝内胆汁うっ滞性疾患の処置
JP5341749B2 (ja) 脂肪肝又は非アルコール性脂肪性肝炎の予防及び／又は治療のための医薬
JP2020516622A (ja) ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
CN101232880A (zh) Hdac抑制剂在治疗骨髓瘤中的用途
US20080269310A1 (en) Synergistic Combinations
US20210401798A1 (en) Lipoxin a4 analogs and uses thereof
JP2020530471A (ja) ＭＥＫ／ＰＩ３Ｋ、ＪＡＫ／ＭＥＫ、ＪＡＫ／ＰＩ３Ｋ／ｍＴＯＲおよびＭＥＫ／ＰＩ３Ｋ／ｍＴＯＲの生物学的経路の阻害剤、および治療化合物のリンパ取り込み、生物学的利用能、および溶解性を改善する方法
JP7596548B2 (ja) 胆管症の治療
JP2023141229A (ja) 高リン血症治療用医薬用組成物
BACHUBHAI SUB-ACUTE ORAL TOXICITY STUDY OF ATORVASTATIN ALONE AND IN COMBINATION WITH VERAPAMIL FOLLOWING REPEATED ADMINISTRATION IN HYPERLIPIDEMIC RATS
BALLI NEXT-GENERATION ANTIHYPERLIPIDEMIC DRUGS
WO2003090735A1 (en) Therapeutic agent for inflammatory intestinal diseases containing hydroxamic acid compound as active ingredient
BR112018076765B1 (pt) Composição para inibir a conversão de colina em trimetilamina (tma)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090916